

DETAILED ACTION

In response to the Pre-Appeal conference, the finality of the previous Office action is hereby withdrawn and the prosecution is re-opened in view of the newly discovered reference(s) to US-PAT-NO: 6479274. Rejections based on the newly cited reference(s) follow. The rejection of record is withdrawn. Claims 8, 9, 14, 15, 18, 19, 23, 24, and 26-45 are pending and examined on merits.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 8, 9, 14, 15, 18, 19, 23, 24, and 26-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over US-PAT-NO: 6479274 (Feb. 13, 1998).

The effective filing date of the instant application, date of filing 60/101522 on 09/23/1999. Testisin is same as the native protein expressed by SEQ ID NO: 1 in 09/787,844 according to applicant's argument in the appeal brief (page 2).

Claims are drawn to detect gynecological cancer with an antibody binding to a protein known as Testisin in the art.

US-PAT-NO: 6479274 (Feb. 13, 1998) teaches:

157

HELA2 (Testisin) Expression is Associated with Tumours in Non-Testis Cell-Types

158

The tissue and cell-type distribution of testisin mRNA transcripts in tumours were determined by Northern hybridization analyses of RNA

Art Unit: 1642

extracted from in vitro cultured tumour cells lines derived from different cancerous tissues. HELA2 (testisin) was detected in the HeLa ovarian carcinoma the U937 lymphoma, and the melanoma cell line 253-3D. HELA2 (testisin) is also associated with cDNA libraries derived from tumours of the colon, pancreas, prostate and ovary (NCBI-EST Database). The presence of HELA2 (testisin) in tumours where it is not expressed normally indicates that it likely plays a role in tumorigenesis in several cell-types.

```

RESULTS
US-59-023-342A-6
SEQUENCE # Application US/59023342A
Patent NO. 6475274
GENERAL INFORMATION
APPLICANT: (US only) ANTALIS Toni Marie and HCOOPER John David
TITLE OF INVENTION: NOVEL MOLECULES
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESS: SICKLY, SCOTT, MURPHY & PFEISER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release 3.1.5, Version #1.25

```

```

Query Match      98.14; Score 1723; DP 4; Length 514;
Seq. Local Similarity 99.74; Prev. No. 2.3e-168;
Matches 512; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 14 NGAGGALLLACILARICLAKPSSQSAARLESQCVITSRVGGCHLALRWHPQOQLR 79
Db 1 NGAGGALLLACILARICLAKPSSQSAARLESQCVITSRVGGCHLALRWHPQOQLR 65
Qy 74 LQENYCVQVLLSNNALTAANKYETZTSLSQFQWQFQGLTSPFSLQAYVYTF 133
Db 61 LQENYCVQVLLSNNALTAANKYETZTSLSQFQWQFQGLTSPFSLQAYVYTF 120
Qy 134 VNNYLSPPYFLNSPYDIALVGLAAPVYTHQDQICQARTSPFNKDTVWYTWYIK 193
Db 123 VNNYLSPPYFLNSPYDIALVGLAAPVYTHQDQICQARTSPFNKDTVWYTWYIK 169
Qy 194 NQALPSPPHTLQGVVALINNSMTHMLKLYVTRKQIFQATYCAHQAQGRKACPDQEL 253
Db 181 NQALPSPPHTLQGVVALINNSMTHMLKLYVTRKQIFQATYCAHQAQGRKACPDQEL 249
Qy 284 PLACVQVGLWYGVGVWQVQCFQPPQGVVYVNIAMKPNVGRMAQAGKMQPQPSWFL 313
Db 241 PLACVQVGLWYGVGVWQVQCFQPPQGVVYVNIAMKPNVGRMAQAGKMQPQPSWFL 306
Qy 314 PPFLNALALGLGV 327
Db 301 PPFLNALALGLGV 314

```

77

Both polyclonal and monoclonal antibodies are obtainable by immunization with the enzyme or protein and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of proteinase/kinase, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they

Art Unit: 1642

are generally less favoured because of the potential heterogeneity of the product.

78

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art.

79

Another aspect of the present invention contemplates a method for detecting proteinase/kinase in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for proteinase/kinase or its derivatives or homologues for a time and under conditions sufficient for an antibody-proteinase/kinase complex to form, and then detecting said complex.

80

The presence of proteinase/kinase may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen by reference to U.S. Pat. Nos. 4,016,043, 4,424,279 and 4,018,653. These, of course, includes both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

81

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabeled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain proteinase/kinase including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph,

Art Unit: 1642

tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

82

In the typical forward sandwich assay, a first antibody having specificity for the proteinase/kinase or antigenic parts thereof, is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from about room temperature to about 37.degree. C.) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.

83

An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

Therefore, it would have been obvious to one of ordinary skill in the art to arrive at the claimed invention of detecting gynecological cancer given the patent teaches that Testisin is overexpressed in ovary and other cancer with a reasonable expectation of success given the, the disclosure of the instant specification and the teaching are is similar (i.e. over-expression of Testisin in non-testis tumors).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MISOOK YU
Primary Examiner
Art Unit 1642

/MISOOK YU/
Primary Examiner, Art Unit 1642